Global expansion AirXpanders has CE Mark and TGA approval and is commercially available in Australia, indicating readiness for broader export opportunities in APAC markets and potential for partnerships to accelerate global adoption of AeroForm.

Patient empowerment AeroForm enables patient-controlled, needle-free expansion at home, a differentiator that can be leveraged to upsell to surgeons and hospital systems seeking reduced clinic visits, faster reconstruction timelines, and improved patient experience.

Financial resilience Historical funding activity including a $10M Series D and ongoing cash flow reporting suggest financiers are supportive, but recent covenant breach issues imply the need for targeted sales to drive revenue growth and restore investor confidence.

Market momentum Launch across more than 100 U.S. institutions and ongoing demand for two-stage reconstruction positions AeroForm as a standard-of-care option; opportunities exist to expand within existing accounts and target large multi-site health systems.

Strategic partnerships The company’s position in reconstructive surgery and commitments to quality and design open avenues for collaborations with plastic surgery centers, distributors, and aftercare services to broaden adoption and enhance training and support infrastructure.